Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Archives of Gynecology and Obstetrics
Published in: Archives of Gynecology and Obstetrics 5/2012

01-05-2012 | Gynecologic Oncology

Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors

Authors: M. Moegele, S. Buchholz, S. Seitz, Olaf Ortmann

Published in: Archives of Gynecology and Obstetrics | Issue 5/2012

Login to get access

Abstract

Introduction

Breast cancer is the most frequent cancer among women with about 1.38 million new cases worldwide every year. Most of these patients are postmenopausal and suffer from hormone receptor positive breast tumors. About 50% of postmenopausal women between 50 and 60 years and 72% of women over 70 years suffer from vulvovaginal athrophy (VVA). Adjuvant treatment with aromatase inhibitors (AIs) improves outcomes in postmenopausal women with hormone receptor positive early stage breast cancer compared with tamoxifen. A frequent side effect of AI use is VVA with symptoms like vaginal dryness, vaginitis, pruritus, dyspareunia and cystitis.

Materials and methods

We searched major databases (i.e. pubmed) with the following selection criteria: breast cancer, hormone therapy, vaginal estrogen, aromatase inhibitor, vaginal atrophy, serum estrogen levels.

Conclusions

Vaginal administration of estradiol is a well known and safe alternative to systemic estrogen therapy, but studies demonstrated significant increases in plasma concentrations of estradiol. Such observations have also been reported in postmenopausal breast cancer patients treated with AIs. Further studies are needed to explore risk of breast cancer recurrence after vaginal estrogen application for patients on adjuvant endocrine therapy with AIs.
Literature
1.
2.
3.
Rossin-Amar B (2000) Vaginal dryness in the menopausal woman (physiological and psychological aspects). Gynecol Obstet Fertil 28:245–249PubMed
4.
Berman JR, Berman LA, Werbin TJ, Goldstein I (1999) Female sexual dysfunction: anatomy, physiology, evaluation and treatment options. Curr Opin Urol 9:563–568PubMedCrossRef
5.
Joslyn SA (2002) Hormon receptors in breast cancer: Racial differences in distribution and survival. Breast Cancer Res Treat 73:45–59PubMedCrossRef
6.
Forbes JF, Cuzick J, Buzdar A et al (2008) Arimidex, tamoxifen, alone or in combination (ATAC) trialists’ group. effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45–53PubMedCrossRef
7.
Kendall A, Dowsett M, Folkerd E, Smith I (2006) Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 17:584–587PubMedCrossRef
8.
Fallowfield L, Cella D, Cuzick J et al (2004) Quality of life of postmenopausal women in the arimidex, tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial. J Clin Oncol 22:4261–4271PubMedCrossRef
9.
Ganz PA, Rowland JH, Desmond K et al (1998) Life after breast cancer: understanding women’s health- related quality of life and sexual functioning. J Clin Oncol 16:501–514PubMed
10.
Höffler D, Lusek R, Berthold HK, Tiaden JD (2003) Arzneimittelkommission der Deutschen Ärzteschaft 2003. Hormontherapie im Klimakterium. Therapieempfehlungen. Arzneiverordnung in der Praxis 3:19–26
11.
New Zealand Guideline Group (NZGG) ( 2001) Best practice evidence-based guideline. The appropriate prescribing of hormone replacement therapy. Published May ISBN: 0-473-44714185
12.
North American Menopause Society (NAMS Board) (2007) Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of the North American Meno-pause Society. Menopause 14:168–182CrossRef
13.
North American Menopause Society (NAMS Board) (2008) Estrogen and progestogen use in post- menopausal women: July 2008 position statement of the North American Menopause Society. Menopause 15:584–603CrossRef
14.
Collins JA, Blake JM, Crosignani PG (2005) Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 11:545–560PubMedCrossRef
15.
16.
Farquhar CM, Marjoribanks J, Lethaby A, Lamberts Q, Suckling JA, The Cochrane HT Study Group (2005) Long-term hormone therapy for perimenopausal and postmenopausal women (review). Cochrane Database Syst Rev 3:CD004143PubMed
17.
Farquhar CM, Marjoribanks J, Lethaby A, Lamberts Q, Suckling JA, and the Cochrane HT Study Group (2008) Long-term hormone therapy for perimenopausal and postmenopausal women (review). In: new search for studies completed, conclusions not changed. The Cochrane Library. 2:CD004143
18.
Greiser CM, Greiser EM, Dören M (2005) Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials. Human Reprod Update 11:561–573CrossRef
19.
20.
Lee SA, Ross RK, Pike MC (2005) An overview of menopausal oestrogen- progestin hormone therapy and breast cancer risk. Br J Cancer 92:2049–2058PubMedCrossRef
21.
Shah NR, Borenstein J, Dubois RW (2005) Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis. Menopause 12:668–678PubMedCrossRef
22.
Beral V (2003) Million Women Study Collaborators: breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427 (Erratum in: Lancet 2003; 362:1160)PubMedCrossRef
23.
Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, Chlebowski RT, Gass M, LaCroix A, Manson JE, Prentice RL, Rossouw J, Stefanick ML (2008) Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 9:1036–1045CrossRef
24.
Ravdin PM, Cronin KA, Howlader N et al (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356:1670–1674PubMedCrossRef
25.
Noss D, Ortmann O (2009) Hormone therapy (HT) and Cancer. J Gynaecol Endokrinol 19:6–10
26.
Holmberg L, Anderson H (2004) HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomized comparison: trial stopped. Lancet 363:453–455PubMedCrossRef
27.
Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B et al (2009) LIBERATE Study Group: safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double- blind, randomized, non inferiority trial. Lancet Oncol. 10:135–146PubMedCrossRef
28.
Von Schoultz E, Rutqvist LE (2005) Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst 97:533–535CrossRef
29.
Vassilopoulou-Sellin R, Theriault R, Klein MJ (1997) Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer. Gynecol Oncol 65:89–93PubMedCrossRef
30.
Wile AG, Opfell RW, Margileth DA (1993) Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 165:372–375PubMedCrossRef
31.
Stoll BA (1989) Hormone replacement therapy in women treated for breast cancer. Eur J Cancer Clin Oncol 25:1909–1913PubMedCrossRef
32.
Powles TJ, Hickish T, Casey S, O’Brien M (1993) Hormone replacement after breast cancer. Lancet 342:60–61PubMedCrossRef
33.
Eden JA, Bush T, Nand S, Wren BG (1995) A case-controlled study of combined continuous hormone replacement therapy amongst women with a personal history of breast cancer. Menopause 2:67–72CrossRef
34.
Ursic-Vrscaj M, Bebar S (1999) A case-control study of hormone replacement therapy after primary surgical breast cancer treatment. Eur J Surg Oncol 25:146–151PubMedCrossRef
35.
Vassilopoulou-Sellin R, Asmar L, Hortobagyi GN et al (1999) Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively. J Clin Oncol 17:1482–1487PubMed
36.
DeSaia PJ, Brewster WR, Ziogas A, Anton-Culver H (2000) Breast cancer survival and hormone replacement therapy: a cohort analysis. Am J Clin Oncol 23:541–545CrossRef
37.
Marsden J, Whitehead M, A’Hern R, Baum M, Sacks N (2000) Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible? Fertil Steril 37:292–299CrossRef
38.
O’Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS (2001) Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 93:754–762PubMedCrossRef
39.
Beckmann MW, Mohrmann T, Kuschel B et al (1998) Hormonersatztherapie (HRT) nach Mammakarzinomerkrankung Ergebnisse einer Beobachtungsstudie. Geburtshilfe Frauenheilkd 58:193–196CrossRef
40.
Col N, Hirota L et al (2001) Hormone replacement therapy after breast cancer: a systemic review and quantitative assessment of risk. J Clin Oncol 19:2357–2363PubMed
41.
Decker D, Pettinga J et al (2003) Estrogen replacement therapy in breast cancer survivors: a matched-controlled series. Menopause 4:277–285CrossRef
42.
Cardozo L, Bachmann G, McClish D, Fonda D, Bigerson L (1998) Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the hormones and urogenital therapy commmittee. Obstet Gyncol 92:722–727CrossRef
43.
Suckling J, Lethaby A, Kennedy R (2003) Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 4:CD001500PubMed
44.
North American Menopause Society (2007) Menopause practice: a clinican’s guide, 3rd edn edn. North American Menopause Society, Mayfield Heights
45.
Nilsson K, Heimer G (1992) Low- dose oestradiol in the treatment of urogentital oestrogen deficiency- a pharmacokinetic and pharmacodynamic study. Maturitas 15:121–127PubMedCrossRef
46.
Sindberg P, Rasmussen H (1992) Low- dose 17β- estradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. Eur J Obstetet Gynecol 44:137–144CrossRef
47.
Ascenzi P, Bodeci A, Marino M (2006) Structure- function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects 27:299–402CrossRef
48.
Ruggiero RJ, Likis FE (2002) Estrogen: physiology, pharmacology, and formulations for replacement therapy. J Midwifery Women’s Health 47:130–138CrossRef
49.
50.
Babuna C, Aksu MF, Erez R (1982) Management of lower genital tract atrophy with a vaginal cream containing oestriol. In: The menopause: clinical endocrinological and pathophysiological aspects. Academic Press, London, pp 557–562
51.
Boselli F, Volpe A, Genazzani AR (1987) Topical therapy: estriol vaginal cream in postmenopausal women: gynecological endocrinology. Parthenon publishing, Carnforth, pp 687–694
52.
Boselli F, Cicoli C, Volpe A, Genazzani AR (1987) Endometrial morphology after long-term topical oestriol therapy in postmenopausal women. In: Abstracts of the 5th International Congress on the Menopause Sorrento. Parthenon Publishing, Carnforth. p 75
53.
Genazzani AR, Inaudi P, La Rosa R, De Leo V, Ricci-Danero MG, Danero S (1980) Estriol and menopause—clinical and endocrinological results of vaginal administration. In: International symposium on the menopause: clinical, endocrinological and pathophysiological aspects
54.
Gerbaldo D, Ferraiolo A, Croce S, Truini M, Capitanio GL (1991) Endometrial morphology after 12 months of vaginal oestriol therapy in postmenopausal women. Maturitas 13:269–274PubMedCrossRef
55.
Kicovic PM, Cortes-Prieto J, Milojevic S, Haspels AA, Aljinovic A (1980) The treatment of postmenopausal vaginal atrophy with Ovestin® vaginal cream or suppositories: clinical, endocrinological and safety aspects. Maturitas 2:275–282PubMedCrossRef
56.
Lauritzen C (1979) Erfahrungen mit einer oestriol-vaginalcreme. Ther Gegenw 118:567–577
57.
Luisi M, Franchi F, Kicovic PM (1980) A group-comparative study of effects of Ovestin® cream versus premarin cream in postmenopausal women with vaginal atrophy. Maturitas 2:311–319PubMedCrossRef
58.
Mattsson LA, Cullberg G (1983) A clinical evaluation of treatment with estriol vaginal cream versus suppository in postmenopausal women. Acta Obstet Gynecol Scand 62:397–401PubMedCrossRef
59.
Foidart JM, Vervliet J, Buytaert Ph (1991) Efficacy of sustained- release vaginal oestriol in alleviating urogenital and systemic climacteric complaints. Maturitas 13:99–107PubMedCrossRef
60.
Fink RS, Collins WP, Papadaki L, O’Reilly B, Ginsburg J (1985) Vaginal estriol: effective menopausal therapy not associated with endometrial hyperplasia. J Gynaecol Endocrinol 1:1–2
61.
Pfeiler G, Glatz C, Königsberg R et al (2011) Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients. Climacteric 14:339–344PubMedCrossRef
62.
Vooijs GP, Geurts TBP (1995) Review of the endometrial safety during intravaginal treatment with estriol. Eur J Obstet Gynecol Reprod Biol 62:101–106PubMedCrossRef
63.
Kendall A, Dowsett M, Folkerd E, Smith I (2006) Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 17:584–587PubMedCrossRef
64.
Labrie F, Cusan L, Gomez JL et al (2009) Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause 16:30–36PubMedCrossRef
65.
Derzko C, Elliott S, Lam W (2007) Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr Oncol 14:20–40CrossRef
66.
Bachmann GA, Nevadunsky NS (2000) Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 61:3090–3096PubMed
67.
Murray A, Freedman MA (2008) Vaginal pH, estrogen and genital atrophy. Menopause Manag 17:9–11
68.
69.
Bygdeman M, Swahn ML (1996) Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in post- menopausal women. Maturitas 23:259–263PubMedCrossRef
70.
Society of Obstetricians, Gynaecologists of Canada (2005) Clinical practice guidelines: the detection and management of vaginal atrophy. Int J Gynaecol Obstet 88:222–228CrossRef
71.
Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Julia MD (2005) Management of post- menopausal vaginal atrophy and atrophic vaginitis. Maturitas 52:46–52CrossRef
72.
Suckling J, Lethaby A, Kennedy R (2003) Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 4:CD001500PubMed
Metadata
Title
Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors
Authors
M. Moegele
S. Buchholz
S. Seitz
Olaf Ortmann
Publication date
01-05-2012
Publisher
Springer-Verlag
Published in
Archives of Gynecology and Obstetrics / Issue 5/2012
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-011-2181-6

Other articles of this Issue 5/2012

Archives of Gynecology and Obstetrics 5/2012 Go to the issue

General Gynecology

Morbidity in elderly women undergoing gynaecological pelvic floor surgery

Maternal-Fetal Medicine

Serum visfatin concentrations in gestational diabetes mellitus and normal pregnancy

Gynecologic Oncology

Investigating the relative efficacies of combination chemotherapy of paclitaxel/carboplatin, with or without anthracycline, for endometrial carcinoma

General Gynecology

Evaluation of patients with Behçet’s disease by cervical cytology and colposcopic examination

Maternal-Fetal Medicine

Court-visited obstetrical and fertility procedures

General Gynecology

Previous cesarean section, gestational age at first delivery and subsequent risk of pre-eclampsia in obese mothers